By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Shares of Blackstone Inc. BX slipped 2.27% to $164.78 Tuesday, on what proved to be an all-around great trading session for ...

The pharmaceutical giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to ...

Retail Opportunity Investments Corp. investors agreed to sell the company for $17.50 per share, a roughly 34% premium from ...

Steve Schwarzman knows a thing or two about wealth. It’s no wonder that Blackstone , the investing colossus he runs, found a ...

Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019 ...

Blackstone Mortgage Trust saw significant losses and foreclosures in Q4. Read why BXMT stock faces challenges with 2025 ...

After making Super Bowl history with Kendrick Lamar in 2022, Willingboro native Adam Blackstone is set to return for a ...

Blackstone, a major global investor in data centers that run A.I. systems, expects use of the technology to rise as the cost ...

--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for ...

Blackstone beat estimates for fourth-quarter profit on Thursday, driven by a pickup in dealmaking, while executives at the ...

Net income for the quarter totaled $1.3 billion, or $0.92 per share, in a 1,120% increase from $109 million a year earlier.